A Look at the Key Issues Driving Growth in the Asian Cardiovascular Market
Posted on: Monday, 30 January 2006, 00:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c31685) has announced the addition of The Asian Cardiovascular Market Outlook to 2010 to their offering.
The Asian Cardiovascular Market Outlook to 2010 is a new management report which provides comprehensive coverage of the major cardiovascular markets in the Asia Pacific region. This report provides detailed analysis of, market trends, epidemiology, current leading brands of treatment, product sales forecast and future market leaders over the period 2005-2010 in nine markets: China, India, Singapore, South Korea, Thailand, Philippines, Malaysia, Indonesia and Taiwan.
The Asia Pacific region is an important market for cardiovascular products; it is estimated to have high prevalence rates for cardiovascular diseases and associated risk factors. However, due to the increasing presence of effective generic medicine and the limited launches of innovative, the threat of underperformance facing major pharmaceutical companies is now very real.
Through analysis and forecasts, this report will allow you to identify the cardiovascular market trends in developed and emerging Asian countries, assess the dominant forces driving market growth and develop potential growth and diversification opportunities in this region over the period 2005-2010.
Geographic coverage...
- China - India - Indonesia - Malaysia - Singapore - South Korea -Taiwan - Thailand - The Philippines
Risk factors covered
- Hypertension - Dyslipidemia - Diabetes
Must have' statistics and analysis in this report
This report provides:
-- Epidemiological analysis and forecast prevalence of the major cardiovascular indications and their sub-indications over the period 2005-10 in the Asia Pacific region.
-- Historical analysis of the performance of leading products in the four therapy areas under study.
-- Company analysis and market share of the top eight players in the cardiovascular area: Pfizer, Sanofi-Aventis, AstraZeneca, Merck, Novartis, Bayer, Roche and GSK.
-- Detailed analysis of forecast potential products in the cardiovascular area of the Asia Pacific region.
-- Head to head performance analysis of leading pharmaceutical corporations and company forecasts to 2010.
Your questions answered
-- What will be the major growth indications in the cardiovascular market over the period 2005-10 in the Asia Pacific region?
-- In the Asia Pacific markets, which companies were the winners and losers in the cardiovascular area in 2004?
-- How have recent major launches from Pfizer, Sanofi-Aventis, AstraZeneca and Merck performed in the Asia Pacific region?
-- In the Asia Pacific region, which companies will become the key players in the cardiovascular area over the period 2005-10?
-- Which products will be impacted by generic competition over the period 2005-10 in the Asia Pacific market?
-- Which pipeline products, in the Asia Pacific region, will be the growth drivers of the future and why?
-- Which indications in the Asia Pacific market are forecast to have the highest levels of market potential over the period 2005-10?
-- What will the competitive landscape in hypertension, thrombosis and dyslipidemia look like in 2010?
Actionable strategies to drive your profits forward
-- Save time and money in research with the report's insightful qualitative and quantitative coverage of: the major cardiovascular indications; the Asia Pacific pharmaceutical markets; and, the eight largest companies currently active in the cardiovascular market.
-- Quick and comprehensive understanding of how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in the cardiovascular marketplace.
-- Gain up-to-date competitive intelligence across the cardiovascular portfolio and understand the major issues affecting key pharmaceutical marketers and product development.
-- Understand which cardiovascular indications have the greatest potential to catalyze franchise growth, and how the pharmaceutical industry is attempting to effectively utilize these opportunities.
-- Compare the franchises of top pharmaceutical marketers across the major indications, and understand how market share of leading companies will change over the next 5 years.
Topics Covered
Executive Summary
Chapter 1 Patient potential
Chapter 2 Regional healthcare and licensing trends
Chapter 3 Regional market analysis
Cardiac therapies sales forecasts
Chapter 4 Key players in the Asian cardiovascular market
Chapter 5 Appendix
List of Figures
List of Tables
Companies Mentioned
- Pfizer - Sanofi-Aventis - Merck & Co - AstraZeneca - Novartis - Bayer - GSK - Roche
For more information visit http://www.researchandmarkets.com/reports/c31685
Source: Business Wire
Related Articles
- Spain Oil and Gas Markets Investment Opportunities Analysis and Forecasts to 2020 Report Profiles Operator and Equity Details for Major Oil and Gas Assets in Spain
- Thailand Oil and Gas Markets Investment Opportunities, Analysis and Forecasts to 2020 Profiles of the Major Companies Operating in the Oil and Gas Sector
- New Zealand Oil and Gas Markets Investment Opportunities Analysis and Forecasts to 2020 Profiles the Major Companies Operating In the Oil and Gas Sector
- Pacific Asia Petroleum, Inc. Information Now Available Through S&P Market Access Program
- Pacific Asia China Energy Inc. Announces Approval to Trade on the OTC Bulletin Board Securities Market in the United States
- Commercial Geostationary Transponder Markets for Asia Pacific Report Out Now
- 6 Years After 9/11: Where is the Homeland Security Market in Asia Pacific Heading?
- Attention: Stem Cell Investors Stem Cell Market Forecast and Analysis 2005-2015 Available Now
- The Approval of Pfizer's Revatio (Sildenafil) and Servier's Procoralan (Ivabradine) is Likely to Have the Largest Impact on the Cardiovascular Market
- Telelogic: Staffan Soderqvist New President of Telelogic's Market Division Asia/Pacific
 |
 |
User Comments (0)
RSS Feeds